← Back to patent-cliff list
Inaxaplin
Tier C — Watch / tradeInaxaplin
Vertex Pharmaceuticals Incorporated
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：ApoL
Indications (approved)：Kidney disease, 局灶性节段性肾小球硬化症
Regional status
US
Phase III
2022-03-30
EU
Phase III
2022-03-30
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Inaxaplin?
Approved indications include: Kidney disease, 局灶性节段性肾小球硬化症.
When does the Inaxaplin patent expire?
No public expiry year is available for Inaxaplin yet; this page updates once verified.
How do I get a quote for Inaxaplin intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-05